Al­ny­lam gets an ad­comm for On­pat­tro treat­ment in AT­TR amy­loi­do­sis

Al­ny­lam Phar­ma­ceu­ti­cals is hop­ing its lat­est round of da­ta for On­pat­tro’s treat­ment of AT­TR is enough to sat­is­fy the FDA. But they’ll have to make it through their ad­vi­sors first.

Al­ny­lam an­nounced Tues­day that the FDA has ac­cept­ed a sup­ple­men­tal NDA for On­pat­tro, oth­er­wise known as patisir­an, to treat the car­diomy­opa­thy of transthyretin-me­di­at­ed (AT­TR) amy­loi­do­sis, and will be hold­ing an ad­vi­so­ry com­mit­tee to dis­cuss the ap­pli­ca­tion. How­ev­er, the date of the ad­comm was not im­me­di­ate­ly dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.